IPF patients exhibit basal CXCL11 levels; however, IFN-γ1b treatment increases BAL and serum CXCL11 levels while decreasing elastin, Type III pro-collagen, and PDGF-B in IPF samples [275]. This evidence concerns the gene CXCL11 and idiopathic pulmonary fibrosis.